Abbott is taking continuous glucose monitoring beyond diabetes treatment with Lingo, a prescription-free wearable that links real-time readings to meals, exercise, sleep and stress. Abbott’s Lingo wearable is part of a fast-growing push to make glucose monitoring available beyond people…
Eliminating carbohydrates may initially cause fatigue and poor concentration, while cutting fibre-rich foods can create new health risks. Experts recommend reducing refined carbs rather than abandoning healthier sources altogether. Cutting out carbohydrates entirely can reshape eating habits quickly, but the…
From Yosemite’s Stonemasters to the Tetons and an Everest expedition, Catherine Cullinane built a pioneering career as a climber, guide and diabetes educator after being diagnosed with Type 1 diabetes. Catherine Cullinane’s life has traced an uncommon line through American…
A new perspective argues that dedicated podiatric hospitalists could bring greater coordination to complex foot and ankle cases, while highlighting the need for evidence on whether the model improves outcomes. A new perspective in the Journal of the American Podiatric…
More than 25,000 diabetes-related consultations have been recorded since April as Gauteng combines expanded podiatry services with a new near-real-time dashboard to identify patients at risk of serious complications. Gauteng’s health department says it is stepping up specialist foot care…
An analysis of more than 300 million US patient records found lower adjusted odds of macular degeneration among people with type 2 diabetes taking GLP-1 medicines, although other studies have reported no link or increased risk. A fresh analysis presented…
The Exeter centre had to balance late selection, long-haul travel and unpredictable blood sugar levels as he returned to England duty and renewed his push towards the 2027 World Cup. Henry Slade’s return to England duty this summer came with…
Early trial results suggest CBL-514 reduced visceral fat by about 12 per cent, but larger studies are needed to establish whether the experimental treatment delivers lasting health benefits. An experimental injection called CBL-514 may offer a way to reduce visceral…
Thousands of Bulgarian patients are being moved from human insulin to fully reimbursed analogues, with supplies expected to continue until 31 May 2027. Thousands of people with diabetes in Bulgaria are being moved from older human insulin preparations to newer…
The Danish drugmaker has expanded its diabetes treatment range in Thailand, while preparing specialist training as competition intensifies in the GLP-1 medicines market. Novo Nordisk has introduced a higher-dose semaglutide option in Thailand, widening the range of treatments available to…
